Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer.

导出 OA

翻译打印收藏纠错

第一作者： Christine Y,Lu

第一单位： Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, 401 Park Drive, Suite 401 East, Boston, MA, 02215, USA. christine_lu@harvardpilgrim.org.

作者： Christine Y,Lu ^[1] ; Fang,Zhang ^[2] ; Anita K,Wagner ^[2] ; Larissa,Nekhlyudov ^[3] ; Craig C,Earle ^[4] ; Matthew,Callahan ^[2] ; Robert,LeCates ^[2] ; Xin,Xu ^[2] ; Dennis,Ross-Degnan ^[2] ; J Frank,Wharam ^[2]

作者单位： Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, 401 Park Drive, Suite 401 East, Boston, MA, 02215, USA. christine_lu@harvardpilgrim.org. ^[1] Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, 401 Park Drive, Suite 401 East, Boston, MA, 02215, USA. ^[2] Department of Medicine, Brigham & Women's Hospital, 800 Huntington Avenue, Boston, MA, 02115, USA. ^[3] Ontario Institute for Cancer Research, 661 University Avenue, Toronto, ON, Canada. ^[4]

关键词 Adjuvant hormonal therapy Aromatase inhibitors Breast cancer care High-deductible health insurance Tamoxifen